Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to -$1.1 million.

  • Caribou Biosciences' Change in Accured Expenses fell 170.41% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 179.20%. This contributed to the annual value of $2.1 million for FY2024, which is 62.84% down from last year.
  • Per Caribou Biosciences' latest filing, its Change in Accured Expenses stood at -$1.1 million for Q3 2025, which was down 261.48% from $688,000 recorded in Q2 2025.
  • Caribou Biosciences' 5-year Change in Accured Expenses high stood at $5.0 million for Q2 2024, and its period low was -$4.1 million during Q1 2023.
  • In the last 3 years, Caribou Biosciences' Change in Accured Expenses had a median value of $688,000 in 2025 and averaged $395,727.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 1,676.44% in 2023, then slumped by 176.23% in 2024.
  • Caribou Biosciences' Change in Accured Expenses (Quarterly) stood at -$574,000 in 2021, then skyrocketed by 281.88% to $1.0 million in 2022, then soared by 177.30% to $2.9 million in 2023, then tumbled by 176.23% to -$2.2 million in 2024, then tumbled by 170.41% to -$1.1 million in 2025.
  • Its Change in Accured Expenses stands at -$1.1 million for Q3 2025, versus $688,000 for Q2 2025 and -$3.1 million for Q1 2025.